Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases

Clinical Pharmacokinetics

Volumn 52, Issue 3, 2013, Pages 187-198

  Yang, Shuying ^a   Lukey, Pauline ^a   Beerahee, Misba ^a   Hoke, Frank ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOSMAPIMOD;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AGED; ARTHRITIS, RHEUMATOID; CROSS-OVER STUDIES; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; YOUNG ADULT;

EID: 84877053470     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0025-6     Document Type: Article

References (23)

1. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem. 2005;5:921-8.
2. Schieven GL. The p38a kinase plays a central role in inflammation. Curr Top Med Chem. 2009;9:1038-48.
3. Goldstein DM, Kuglstatter A, Lou Y, et al. Selective p38r inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010;53:2345-53.
4. Aston NM, Bamborough P, Buckton JB, et al. p38α Mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem. 2009;52:6257-69.
5. GSKClinicalStudyRegister.com identifier: HM2010/00107/00, study no. PM1113022. Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous dose(s) and a single oral dose of GW856553 in healthy volunteers. http://www.gsk-clinicalstudyregister.com/result- detail.jsp?protocolId=113022&studyId=1E5A07BD-2DA1-492B-B305- 38AEBC275A62&compound=losmapimod. Accessed 28 Nov 2012.
6. ClinicalTrials.gov identifier: NCT01218126. Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, dose ranging study to evaluate the efficacy and safety of losmapimod tablets administered twice daily compared with placebo for 24 weeks in adult subjects with chronic obstructive pulmonary disease (COPD). 2010. http://clinicaltrials.gov/ct2/show/NCT01218126. Accessed 28 Nov 2012.
7. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2012;52(3):416-24.
8. ClinicalTrials.gov identifier: NCT00633022. A study to evaluate the effects of 3 months dosing with GW856553, as assessed FDG-PET/CT imaging. 2008. http://clinicaltrials.gov/ct2/show/NCT00633022. Accessed 28 Nov 2012.
9. Lukey PT, Perry HC, Yang S, et al. Single doses of p38 MAP kinase inhibitors and prednisolone affect biomarkers in patients with active rheumatoid arthritis (RA). Open J Immunol. 2012;2(3):85-97.
10. Cheriyan J, Webb AJ, Sarov-Blat L, et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation. 2011;123:515-23.
11. Beal SL, Sheiner LB, Boeckmann AJ, editors. NONMEM users guides (1989-2006). Ellicott City: ICON Development Solutions; 2006.
12. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90:154-66.
13. Brendel K, Comets E, Laffont C, et al. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn. 2010;37:49-65.
14. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides (1989-2009). Ellicott City: Icon Development Solutions; 2009.
15. ClinicalTrials.gov identifier: NCT01541852. Losmapimod in chronic obstructive pulmonary disease patients stratified by fibrinogen (EVOLUTION). http://clinicaltrials.gov. Accessed 28 Nov 2012.
16. ClinicalTrials.gov identifier: NCT00910962. a study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST-segment elevation (Solstice). http://clinicaltrials.gov/ ct2/show/NCT01541852. Accessed 28 Nov 2012.
17. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711-26.
18. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1):S41-67.
19. ClinicalTrials.gov identifier: NCT00642148. A 12 week study to assess efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD). 2008. http://clinicaltrials.gov/ct2/show/NCT00642148?term= NCT00642148&rank=1. Accessed 28 Nov 2012.
20. ClinicalTrials.gov identifier: NCT00393146. A study to investigate the effect of 28 days of dosing with GW856553 on patients with rheumatoid arthritis. 2006. http://clinicaltrials.gov/ct2/show/NCT00393146?term=NCT00393146&rank= 1. Accessed 28 Nov 2012.
21. Ogungbenro K, Dokoumetzidis A, Aarons L. Application of optimal design methodologies in clinical pharmacology experiments. Pharm Stat. 2009;8:239-52.
22. Ogungbenro K, Aarons L. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments. Pharm Stat. 2010;9:255-68.
23. Yang S, Beerahee M. Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies. Eur J Clin Pharmacol. 2011;67:225-33.